Table 1 Baseline patient characteristics of group_PRO, group_REDPRO and group_NOPRO

Female; n; %

48

52%

6

46%

15

54%

Male; n; %

44

48%

7

54%

13

46%

Age (years); median; interquartile range

59

52-66

58

51-66

58

50-63

Malignancy; n; %

 • Uveal melanoma

57

62%

13

100%

14

46%

 • Biliary tract cancer

17

19%

-

-

5

17%

 • Hepatocellular carcinoma

6

7%

-

-

1

4%

 • Mammary carcinoma

1

1%

-

-

5

17%

 • Colorectal carcinoma

3

3%

-

-

1

4%

 • NET carcinoma

2

1%

-

-

1

4%

 • Pancreatic carcinoma

2

2%

-

-

-

-

 • Periampullary carcinoma

3

3%

-

-

-

-

 • Endometrial carcinoma

1

1%

-

-

-

-

 • Soft tissue sarcoma

-

-

-

-

1

4%

Comorbidities; n; %

 • Hypertension

32

35%

3

23%

15

54%

 • Diabetes mellitus

8

9%

3

23%

5

18%

 • Thyroid disorder

13

14%

6

46%

3

11%

 • Rhythm disorder 

3

2%

2

15%

2

4%

 • Secondary malignoma

2

2%

-

-

-

-

No. of PHP per patient; median; min-max

2

1-8

2

1-4

2

1-8

Treatments prior to PHP; n; %

 • Liver resection

14

15%

3

23%

5

18%

 • Systemic chemotherapy

24

26%

1

8%

11

39%

 • Surgery and systemic chemotherapy

6

7%

-

-

3

11%

 • Immunotherapy

10

11%

2

15%

6

21%

 • locoregional/intraarterial liver therapy other than PHP

16

18%

3

23%

6

21%

 • No previous (liver directed) treatments

24

26%

4

31%

7

25%